Similar articles

• The role of newer monoclonal antibodies in renal transplantation.

  Vincenti F. Vincenti F. Transplant Proc. 2001 Feb-Mar;33(1-2):1000-1. doi: 10.1016/s0041-1345(00)02303-4. Transplant Proc. 2001. PMID: 11267163 Review. No abstract available.
• Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.

  Burke GW, Ciancio C, Blomberg BB, Rosen A, Suzart K, Roth D, Kupin W, Esquenazi V, Miller J. Burke GW, et al. Transplant Proc. 2002 Aug;34(5):1610-1. doi: 10.1016/s0041-1345(02)03042-7. Transplant Proc. 2002. PMID: 12176505 Clinical Trial. No abstract available.
• Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.

  Martins L, Henriques AC, Dias L, Sarmento AM, Pereira MC, Guimarães S. Martins L, et al. Transplant Proc. 2000 Dec;32(8):2623-5. doi: 10.1016/s0041-1345(00)01810-8. Transplant Proc. 2000. PMID: 11134730 Clinical Trial. No abstract available.
• Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients.

  Ciancio G, Burke GW, Suzart K, Mattiazzi A, Rosen A, Zilleruello G, Abitbol C, Montane B, Miller J. Ciancio G, et al. Transplant Proc. 2002 Aug;34(5):1944-5. doi: 10.1016/s0041-1345(02)03131-7. Transplant Proc. 2002. PMID: 12176637 Clinical Trial. No abstract available.
• Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.

  Pascual J, Marcén R, Ortuño J. Pascual J, et al. Nephrol Dial Transplant. 2001 Sep;16(9):1756-60. doi: 10.1093/ndt/16.9.1756. Nephrol Dial Transplant. 2001. PMID: 11522853 Review. No abstract available.